Search
Edivoxetine
go.drugbank.com/drugs/DB09184InvestigationalEdivoxetine is a drug which acts as a selective norepinephrine reuptake inhibitor and is currently under development by Eli Lilly for attention-deficit hyperactivity disorder (ADHD) and as an antidepressant
Crotamiton
go.drugbank.com/drugs/DB00265ApprovedCrotamiton is a scabicidal and antipruritic agent available as a cream or lotion for topical use only. It is a colorless to slightly yellowish oil, having a faint amine-like odor. It is miscible with alcohol and with methanol.
Bentoquatam
go.drugbank.com/drugs/DB00516ApprovedBentoquatam is a topical medication intended to act as a shield against exposure to the irritating substance urushiol, found in plants such as poison ivy or poison oak. Bentoquatam contains bentonite, a clay, and is only effective as lon...
Zanamivir
go.drugbank.com/drugs/DB00558ApprovedInvestigationalA guanido-neuraminic acid that is used to inhibit neuraminidase.
Patiromer
go.drugbank.com/drugs/DB09263ApprovedInvestigationalPatiromer is a powder for suspension in water for oral administration, approved in the U.S. as Veltassa in October, 2015. Patiromer is supplied as patiromer sorbitex calcium which consists of the active moiety, patiromer, a non-absorbed ...
EHT899
go.drugbank.com/drugs/DB05108ExperimentalEHT899 is a proprietary formulation of an HBV viral protein designed to eliminate the undesirable immune response elicited by the HBV infection.
Zelenirstat
go.drugbank.com/drugs/DB15567InvestigationalZelenirstat (PCLX-001) is a first-in-kind N-Myristoyltransferase (NMT) inhibitor being developed by [Pacylex Pharmaceuticals](https://pacylex.com).
CTx-PDE6b
go.drugbank.com/drugs/DB17858InvestigationalBeing commercialied by Coave Therapeutics, it is being investigated for the treatment of retinitis pigmentosa due to _PDE6b_ gene mutations.[L46757]
GX-19 Vaccine
go.drugbank.com/drugs/DB15891InvestigationalThe GX-19 vaccine is a DNA vaccine created by Genexine, Inc. Company in Gyeonggi, Korea[A219758].
MF101
go.drugbank.com/drugs/DB05052InvestigationalMF101 is a novel estrogen receptor beta (ERβ) selective agonist and unlike currently available hormone therapies, does not activate the estrogen receptor alpha (ERα), known to be implicated in tumor formation. MF101 is an oral drug desig...